| Ytd | -55.04% | |
| 1y | -66.93% |
| Open | 0.75 | Prev Close | 0.74 | Low | 0.74 | High | 0.87 | Mkt Cap | 37.49M |
| Vol | 107.54K | Avg Vol | 127.51K | EPS | -0.73 | P/E | -1.10 | Forward P/E | -4.15 |
| Beta | 0.81 | Short Ratio | 2.26 | Inst. Own | 40.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-04 | 50-d Avg | 0.74 | 200-d Avg | 1.44 | 1yr Est | 4.75 |
NSPR News
MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company
Ms. Kennedy returns to InspireMD having previously served as Sales Director supporting the initial U
NSPR's positive CGUARDIANS II data show 100% acute device success, supporting a potential FDA approv
MIAMI, June 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Compan
InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuar
MIAMI, June 11, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company
InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuar
MIAMI, June 08, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company
InspireMD, Inc. (NSPR) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remark
MIAMI, May 06, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”
Piper Sandler analyst Adam Maeder reiterates InspireMD (NASDAQ:NSPR) with a Overweight and lowers
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus
InspireMD, Inc. (NSPR) Q1 2026 Earnings Call Transcript
InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.16) per share which beat the analyst consen
- Reports total Q1 2026 revenue of $3.4 million, representing year-over-year growth of 122% - - Rece
2026 Financial GuidanceConcurrent with today's announcement, the Company is withdrawing its prio
- Strong clinical demand continues in Q1 2026 with global year-over-year unit sales growth of 53% an
InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD," or the "Company"), developer of the CGua
InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuar
- Strong clinical demand continues in Q1 2026 with global year-over-year unit sales growth of 53% an
MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”
MIAMI, April 27, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Pr
NEW YORK, April 14, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating
InspireMD (NSPR) has become technically an oversold stock now, which implies exhaustion of the heavy
InspireMD, Inc. (NYSE: NSPR - Get Free Report) was down 6.7% on Tuesday. The stock traded as low as
MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® P
InspireMD, Inc. (NSPR) Q4 2025 Earnings Call Transcript
InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.14) per share which beat the analyst consen
InspireMD, Inc. (Nasdaq: NSPR) ("InspireMD" or the "Company"), developer of the CGua
InspireMD, Inc. (Nasdaq: NSPR) ("InspireMD" or the "Company"), developer of the CGua
InspireMD, Inc. (the "Company") (NASDAQ:NSPR), developer of the CGuard Prime Carotid Stent S
Piper Sandler analyst Adam Maeder maintains InspireMD (NASDAQ:NSPR) with a Overweight and lowers
InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.22) per share which missed the analyst cons